circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

BACKGROUND: Approximate 25% HER2-positive (HER2(+)) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms underlying trastuzumab resistance remained largely unclear. METHODS: Trastuzumab-resistant associated circRNAs were identified by circRNAs high-throughpu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Yun, Liang, Gehao, Lin, Qun, Fang, Xiaolin, Luo, Qing, Cen, Yinghuan, Mehrpour, Maryam, Hamai, Ahmed, Liu, Zihao, Shi, Yu, Li, Juanmei, Lin, Wanyi, Jia, Shijie, Yang, Wenqian, Liu, Qiang, Song, Erwei, Li, Jun, Gong, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722291/
https://www.ncbi.nlm.nih.gov/pubmed/34980129
http://dx.doi.org/10.1186/s12943-021-01476-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722291/
https://www.ncbi.nlm.nih.gov/pubmed/34980129
http://dx.doi.org/10.1186/s12943-021-01476-7

Ejemplares similares